Session Details

Moderators
Sarah Nikiforow, MD, PhD, Assistant Professor of Medicine, Harvard Medical School, USA
Bruce Levine, PhD, Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania, USA

Panelists
Denis Claude Roy, MD, Professor Medicine,Hopital Maisonnneuve-Rosemont, CR-HMR, Universite de Montreal Faculte de Medecine, Canada
Patrick Hanley, PhD, Chief and Director, Cellular Therapy Program Associate Professor of Pediatrics, Children's National Hospital, USA
John Rasko, MBBS PhD FRCPA FRACP, Director, Royal Prince Alfred Hospital, Australia
Patricia Rocco, MD, PhD, Federal University of Rio de Janeiro, Brazil

Session Description

• As increasing numbers of commercial CAR-T cell product become available globally, sustainability of field growth will require streamlining and standardization of workflows by all stakeholders.  We plan to discuss common challenges and potential solutions in various countries with an internal panel including representatives from ISCT, FACT, and ASTCT’s 80/20 Committee. 

1. Identify common pain points in commercial CAR or stem cell gene therapy start-up among different countries, regulatory bodies, sponsors and products
2. Brainstorm potential solutions or ongoing initiatives to facilitate these processes for clinical site, commercial sponsor and accrediting bodies
3. Facilitate transparency regarding common themes in the cell therapy field to enable continued global growth